Our story

Advanced peptide research. Delivered.

Vion Labs develops advanced peptide delivery platforms. Our formulations feature retatrutide — the triple-agonist metabolic peptide — supplied in two complementary formats: a sublingual SNEDDS nanoemulsion for oral-mucosa delivery, and a pre-filled research pen for subcutaneous administration.

Retatrutide is one of the most promising next-generation metabolic peptides, combining GIP, GLP-1, and glucagon receptor activity in a single molecule. Our platform supplies it in laboratory-ready formats for controlled R&D applications — including compound stability analysis, formulation studies, and delivery-mechanism evaluation.

We are focused on one thing: producing effective peptide research materials to a consistent, verifiable standard. That means pharmaceutical-grade excipients, industrial manufacturing standards, third-party testing on every batch, and cold-chain dispatch on every order.

Our team

Our formulations were developed by a multidisciplinary team of MD- and PhD-level pharmaceutical scientists and physicians, with more than 60 years of combined experience in formulation development and advanced peptide delivery. Additional detail is available on request — reach us at hello@vionlabs.co.

This site is a work in progress. Product claims, medical language, and regulatory statements are placeholders pending review by our medical and legal advisors. Not intended to diagnose, treat, cure, or prevent any disease.